Navigation Links
Exosomal release of beta-catenin may explain why CD82 and CD9 suppress tumor metastasis
Date:9/13/2010

Researchers reveal a new way in which cells restrain beta-catenin and potentially suppress tumor metastasis: the protein can be ejected from cells in small vesicles called exosomes. The study appears online on September 13 in the Journal of Cell Biology (www.jcb.org).

Beta-catenin is a central component of the Wnt signaling pathway that controls cell proliferation and differentiation. Activation of the Wnt pathway stabilizes beta-catenin, allowing it to move into the cell nucleus and control the expression of many different genes.

Michael Caplan's group at Yale University uncovered a new way in which cells restrain beta-catenin's activity. Overexpressing CD82 or CD9, members of the tetraspanin family of transmembrane proteins, suppressed Wnt signaling and reduced beta-catenin protein levels. Surprisingly, this decrease did not involve an established pathway of beta-catenin destruction. "We were sort of stumped," Caplan admits, "until we saw a talk that mentioned that tetraspanins like CD82 are associated with exosomes."

Exosomes are small vesicles that form inside endosomes by the inward budding of endosomal membranes. The vesicles are then secreted when the endosome fuses with the plasma membrane. The team found that CD9 and CD82 boosted the release of exosomes containing beta-catenin, thereby reducing cellular levels of the protein and inhibiting the Wnt pathway. Cells lacking CD9, on the other hand, produced fewer exosomes and showed higher Wnt signaling activity.

The exosomal release of beta-catenin may be compromised in certain cancers, where Wnt signaling is often hyperactive. CD82 and CD9 are both suppressors of metastasis whose expression is lost in several types of late stage tumor. Caplan and colleagues blocked Wnt signaling in a metastatic cell line after restoring CD82 expression. "CD82 may act as a metastasis suppressor by targeting beta-catenin for exosomal release and thereby reducing its availability as a Wnt signaling mediator," Caplan proposes.


'/>"/>

Contact: Rita Sullivan
news@rupress.org
212-327-8603
Rockefeller University Press
Source:Eurekalert  

Related medicine news :

1. Research!America releases vaccines fact sheet
2. HIV care providers and researchers applaud release of national HIV/AIDS strategy
3. New Release of Wombat Security Technologies' Cyber Security Training Game: Anti-Phishing Phil
4. MedPage Today Releases Free App for Android Phones
5. Bellaboo Releases One Girl At A Time Documentary
6. Relax, Release and Rejuvenate at Upcoming Women's Retreat
7. Purity Products Releases Alpha 3C
8. AAO-HNS releases consensus statement: diagnosis and management of nasal valve compromise
9. Resource guide for internists released by ACP
10. Apps For All Releases New iPhone/iPad Trend Setting App – Mood Lifters
11. DrFinders Releases Searchable Online Directory of Doctors for All Medical Needs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Exosomal release of beta-catenin may explain why CD82 and CD9 suppress tumor metastasis
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation of Christian ... Bible teacher residing in North Carolina with his wife, Anna Marie. He and his ... six grandchildren. David is also the author of “Shadow and Substance.” , “Love, the ...
(Date:3/23/2017)... CO (PRWEB) , ... March 23, 2017 , ... A ... bar for entry into teacher preparation programs. The NCTQ report suggests, based on a ... entry requirements would significantly improve teacher quality in the U.S. It argues that this ...
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd (PWE) Oklahoma City, on ... Avenue, will be an educational and exciting program providing busy clinicians and allied ... chronic pain. , Oklahoma is in a healthcare crisis. The state ranks 46th ...
(Date:3/23/2017)... OH (PRWEB) , ... March ... ... insurance and financial services firm serving the families and businesses of the ... community enrichment program. Northern Ohio Recovery Center (N.O.R.A.) is a nonprofit, community-based ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... investment in Los Angeles based healthcare technology company California Healthcom Group (CHG). ... the US, and healthcare arena. With headquarters in California, CHG is a growing, ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The IPF pipeline is very strong with a total of 97 drug ... Biogen and Sanofi are involved in the development of the IPF therapeutics. ... in Phase III stage, 15 are in Phase II stage, 12 are ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... Supplies - Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a ...
(Date:3/24/2017)... 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... oncology and dermatology biopharmaceutical company, today disclosed terms ... Sheet (the "Definitive Financing") it entered into on ... stockholders, who are referred to in the Definitive ... filed with the Securities and Exchange Commission.   ...
Breaking Medicine Technology: